Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges
Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency announced Monday.
1970-01-01 08:00
